AI system for rehabilitation exercises in breast cancer survivors
Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: A Randomized Controlled Trial
This study tests a new AI program that helps breast cancer survivors do rehabilitation exercises to ease joint pain and stiffness caused by their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06642948 on ClinicalTrials.gov |
What this trial studies
This study develops and evaluates an AI-based skeletal recognition system aimed at enhancing rehabilitation exercises for breast cancer survivors experiencing musculoskeletal symptoms due to endocrine therapy. The intervention focuses on real-time, interactive exercise programs to alleviate issues such as joint pain and stiffness associated with aromatase inhibitors. Participants will be postmenopausal women with hormone receptor-positive breast cancer who are currently undergoing treatment with these inhibitors. The study aims to improve the quality of life for these patients through targeted rehabilitation.
Who should consider this trial
Good fit: Ideal candidates are postmenopausal women with hormone receptor-positive breast cancer currently treated with aromatase inhibitors and experiencing musculoskeletal symptoms.
Not a fit: Patients with recurrent breast cancer, distant metastasis, or other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce musculoskeletal symptoms and improve the quality of life for breast cancer survivors undergoing endocrine therapy.
How similar studies have performed: While the use of AI in rehabilitation is an emerging field, similar studies have shown promise in improving patient outcomes, making this approach both innovative and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Pathologically confirmed hormone receptor-positive breast cancer (stage I, II, III). 2\. Initiation of treatment with aromatase inhibitors (e.g., anastrozole, letrozole, exemestane). 3\. Postmenopausal women, including those with surgically induced menopause. 4. Clear consciousness, no cognitive or communication impairments, and able to comply with the intervention. 5\. Informed consent obtained, with voluntary participation in the study. 6. Bone and joint symptoms with a Brief Pain Inventory (BPI) score of ≥3, or presence of at least one of the following risk factors: elevated bone turnover markers, reduced vitamin D levels, increased inflammatory cytokines, elevated C-reactive protein, or elevated rheumatoid factor. 7\. Not participating in any physical therapy or exercise-based interventions that may interfere with this study. Exclusion Criteria: \- 1. Recurrence of breast cancer or distant metastasis. 2. Presence of other malignancies. 3. Diagnosed rheumatoid arthritis, bone and joint trauma, or other severe bone and joint diseases. 4\. Bone mineral density T-score \<-2.5. 5. Presence of absolute contraindications to exercise.
Where this trial is running
Shanghai
- Shanghai Cancer Center — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Lingyun Jiang
- Email: 22211170029@m.fudan.edu.cn
- Phone: (+86) 18359374969
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.